Cipla reports 32 percent increase in net profit to Rs 1056 crore in Q3
Cipla MD and Global CEO Umang Vohra said the company's topline growth for the quarter was 14 per cent year-on-year.
Bengaluru: Drug major Cipla has reported a 32 percent increase in consolidated net profit at Rs 1,056 crore for the December quarter, on the back of robust sales across geographies.
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai. Cipla has extended its presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. The Company is also deepening its presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
Original news source: https://www.ptinews.com/story/business/cipla-reports-32-pc-rise-in-net-profit-to-rs-1-056-cr-in-q3/1234439
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.